DUBLIN–(BUSINESS WIRE)–The “Chronic Lymphocytic Leukemia – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This Chronic lymphocytic leukemia – Pipeline Insight, 2021 report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic lymphocytic leukemia pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic lymphocytic leukemia R&D. The therapies under development are focused on novel approaches to treat/improve Chronic lymphocytic leukemia.
Chronic lymphocytic leukemia Emerging Drugs Chapters
This segment of the Chronic lymphocytic leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic lymphocytic leukemia Emerging Drugs
Ublituximab: TG Therapeutics
Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell.
The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ (umbralisib), the Company’s once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2022.
LOXO305: Loxo Oncology
Pirtobrutinib is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells.
Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia.
Cirmtuzumab: Oncternal Therapeutics
Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development, that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells, but does not recognize most normal adult tissues.
Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL.
Olaptesed pegol: NOXXON Pharma
NOX-A12 (olaptesed pegol) is currently under Phase II stage of development as a combination therapy in multiple oncology indications. NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine (signaling) protein. NOX-A12 is designed to fight solid tumors by modulating the tumor microenvironment in two distinct ways: Break tumor protection enabling anti-cancer immune cells, such as killer T-cells, to enter the tumor with the aim of unleashing the full potential of immuno-oncology approaches, such as immune checkpoint inhibitors and Block tumor repair through preventing the attraction of ‘repair cells’ to the tumors obstructing tumor re-growth following radiotherapy.
Chronic lymphocytic leukemia: Therapeutic Assessment
This segment of the report provides insights about the different Chronic lymphocytic leukemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic lymphocytic leukemia
There are approx. 60+ key companies which are developing the therapies for Chronic lymphocytic leukemia. The companies which have their Chronic lymphocytic leukemia drug candidates in the most advanced stage, i.e. Preregistration include, TG Therapeutics.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic lymphocytic leukemia drugs?
- How many Chronic lymphocytic leukemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic lymphocytic leukemia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic lymphocytic leukemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic lymphocytic leukemia and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Topics Covered:
Introduction
Executive Summary
Chronic lymphocytic leukemia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Ublituximab: TG Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Cirmtuzumab: Oncternal Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
NX-2127: Nurix
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Key Companies
Key Products
Unmet Needs
Market Drivers and Barriers
Future Perspectives and Conclusion
Analyst Views
Key Companies
- Octapharma
- Celgene
- Loxo Oncology
- Janssen Research & Development, LLC
- TG therapeutics
- AFA Insurance
- MorphoSys AG
- Bristol Myers Squibb
- IO Biotech
- Astex Pharmaceuticals
- Novartis
- Oncternal Therapeutics
- Cellectar Biosciences, Inc.
- Zhejiang DTRM Biopharma
- Incyte Corporation
- Millennium Pharmaceuticals, Inc.
- NOXXON Pharma
- Merck Sharp & Dohme Corp
- Genentech, Inc.
- Rhizen Pharmaceuticals
- Gilead Sciences/Ono Pharmaceutical
- BioInvent International AB
- Chongqing Precision Biotech Co., Ltd
- Mustang Bio
- Genmab
- Genor Biopharma Co., Ltd.
- Iovance Biotherapeutics
- Juno therapeutics
- Lava Therapeutics
- Miltenyi Biomedicine GmbH
- Ascentage Pharma
- Aprea Therapeutics
- BeiGene
- Acerta Pharma BV
- Telios Pharma, Inc.
- NovalGen Ltd.
- Nurix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/1qnocr
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900